PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. (Q45903277)
Jump to navigation
Jump to search
scientific article published on 15 December 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. |
scientific article published on 15 December 2011 |
Statements
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab (English)
J D Jensen
A V Laenkholm
M B Jensen
E Santoni-Rugiu
M Andersson
15 December 2011